Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways - PubMed (original) (raw)
. 2000 Dec 1;96(12):3907-14.
R Fenski, H Halfter, I Matsumura, R Schmidt, C Müller, W Grüning, K Kratz-Albers, S Serve, C Steur, T Büchner, J Kienast, Y Kanakura, W E Berdel, H Serve
Affiliations
- PMID: 11090077
Free article
Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways
M Mizuki et al. Blood. 2000.
Free article
Abstract
Somatic mutations of the receptor tyrosine kinase Flt3 consisting of internal tandem duplications (ITD) occur in 20% of patients with acute myeloid leukemia. They are associated with a poor prognosis of the disease. In this study, we characterized the oncogenic potential and signaling properties of Flt3 mutations. We constructed chimeric molecules that consisted of the murine Flt3 backbone and a 510-base pair human Flt3 fragment, which contained either 4 different ITD mutants or the wild-type coding sequence. Flt3 isoforms containing ITD mutations (Flt3-ITD) induced factor-independent growth and resistance to radiation-induced apoptosis in 32D cells. Cells containing Flt3-ITD, but not those containing wild-type Flt3 (Flt3-WT), formed colonies in methylcellulose. Injection of 32D/Flt3-ITD induced rapid development of a leukemia-type disease in syngeneic mice. Flt3-ITD mutations exhibited constitutive autophosphorylation of the immature form of the Flt3 receptor. Analysis of the involved signal transduction pathways revealed that Flt3-ITD only slightly activated the MAP kinases Erk1 and 2 and the protein kinase B (Akt) in the absence of ligand and retained ligand-induced activation of these enzymes. However, Flt3-ITD led to strong factor-independent activation of STAT5. The relative importance of the STAT5 and Ras pathways for ITD-induced colony formation was assessed by transfection of dominant negative (dn) forms of these proteins: transfection of dnSTAT5 inhibited colony formation by 50%. Despite its weak constitutive activation by Flt3-ITD, dnRas also strongly inhibited Flt3-ITD-mediated colony formation. Taken together, Flt3-ITD mutations induce factor-independent growth and leukemogenesis of 32D cells that are mediated by the Ras and STAT5 pathways. (Blood. 2000;96:3907-3914)
Similar articles
- AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.
Choudhary C, Schwäble J, Brandts C, Tickenbrock L, Sargin B, Kindler T, Fischer T, Berdel WE, Müller-Tidow C, Serve H. Choudhary C, et al. Blood. 2005 Jul 1;106(1):265-73. doi: 10.1182/blood-2004-07-2942. Epub 2005 Mar 15. Blood. 2005. PMID: 15769897 - RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation.
Schwäble J, Choudhary C, Thiede C, Tickenbrock L, Sargin B, Steur C, Rehage M, Rudat A, Brandts C, Berdel WE, Müller-Tidow C, Serve H. Schwäble J, et al. Blood. 2005 Mar 1;105(5):2107-14. doi: 10.1182/blood-2004-03-0940. Epub 2004 Nov 9. Blood. 2005. PMID: 15536149 - [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
Müller-Tidow C, Steur C, Mizuki M, Schwäble J, Brandts C, Berdel WE, Serve H. Müller-Tidow C, et al. Dtsch Med Wochenschr. 2002 Oct 18;127(42):2195-200. doi: 10.1055/s-2002-34942. Dtsch Med Wochenschr. 2002. PMID: 12397548 German. - Role of FLT3 in leukemia.
Gilliland DG, Griffin JD. Gilliland DG, et al. Curr Opin Hematol. 2002 Jul;9(4):274-81. doi: 10.1097/00062752-200207000-00003. Curr Opin Hematol. 2002. PMID: 12042700 Review. - Flt3 receptor tyrosine kinase as a drug target in leukemia.
Schmidt-Arras D, Schwäble J, Böhmer FD, Serve H. Schmidt-Arras D, et al. Curr Pharm Des. 2004;10(16):1867-83. doi: 10.2174/1381612043384394. Curr Pharm Des. 2004. PMID: 15180525 Review.
Cited by
- Synergistic effect of FMS-like tyrosine kinase-3 (FLT3) inhibitors combined with a CDK7 inhibitor in FLT3-ITD-mutated acute myeloid leukemia.
Koo BK, Choi EJ, Moon JH, Kim JY, Park H, Park HS, Choi Y, Lee JH, Lee KH, Choi EK, Kim E, Lee JH, Hur EH. Koo BK, et al. Blood Cancer J. 2024 Sep 16;14(1):161. doi: 10.1038/s41408-024-01141-4. Blood Cancer J. 2024. PMID: 39285195 Free PMC article. No abstract available. - T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting.
Anderson GSF, Chapman MA. Anderson GSF, et al. Mol Ther. 2024 Sep 4;32(9):2856-2891. doi: 10.1016/j.ymthe.2024.07.028. Epub 2024 Aug 5. Mol Ther. 2024. PMID: 39095991 Review. - The roles of phosphorylation of signaling proteins in the prognosis of acute myeloid leukemia.
Márton A, Veres KB, Erdődi F, Udvardy M, Illés Á, Rejtő L. Márton A, et al. Pathol Oncol Res. 2024 Jul 5;30:1611747. doi: 10.3389/pore.2024.1611747. eCollection 2024. Pathol Oncol Res. 2024. PMID: 39035053 Free PMC article. - Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling.
Chen M, Shen C, Chen Y, Chen Z, Zhou K, Chen Y, Li W, Zeng C, Qing Y, Wu D, Xu C, Tang T, Che Y, Qin X, Xu Z, Wang K, Leung K, Sau L, Deng X, Hu J, Wu Y, Chen J. Chen M, et al. Cell Rep Med. 2024 Jul 16;5(7):101645. doi: 10.1016/j.xcrm.2024.101645. Cell Rep Med. 2024. PMID: 39019012 Free PMC article. - FLT3/CD99 Bispecific Antibody-Based Nanoparticles for Acute Myeloid Leukemia.
Ali A, Phan A, Vaikari V, Park M, Pospiech M, Chu R, Meng Y, MacKay JA, Alachkar H. Ali A, et al. Cancer Res Commun. 2024 Aug 1;4(8):1946-1962. doi: 10.1158/2767-9764.CRC-24-0096. Cancer Res Commun. 2024. PMID: 39007347 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous